Brought to you by 
Advanced BioHealing gets $25.5mm in Series C
28 Feb 2007
Executive Summary
Advanced BioHealing (cell-based and tissue engineered products for wound healing) raised $25.5mm through its Series C round that was led by Safeguard Scientifics. Channel Medical Partners, Red Abbey Venture Partners, Canaan Partners, and Wheatley Partners also participated. ABH will put the funds towards the recent launch of its diabetic foot ulcer product Dermagraft, which the company bought from Smith & Nephew last year.
Deal Industry
- Medical Devices
-
Medical Devices
- Biomaterials
-
Biotechnology
- Gene Therapy, Cell Therapy
Deal Status
- Final
Deal Type
-
Financing
- Venture Financing
Already a Biomedtracker subscriber?
You have access to the full deal record through your subscription
Want to become a subscriber?
Subscribers get more deal details, updates, deal financials and deal products.
Questions?
Questions?
Please contact Sales at: (212) 520-2765 or email PharmaNewsSales@informa.com
Related Companies
You must sign in to use this functionality
Authentication.SignIn.HeadSignInHeader
Advanced BioHealing gets $25.5mm in Series C
Email Deal
All set! This article has been sent to my@email.address.
All fields are required. For multiple recipients, separate email addresses with a semicolon.
DCD.EmailPopout.Notice